[go: up one dir, main page]

FI971018L - Farmaseuttisia yhdisteitä - Google Patents

Farmaseuttisia yhdisteitä Download PDF

Info

Publication number
FI971018L
FI971018L FI971018A FI971018A FI971018L FI 971018 L FI971018 L FI 971018L FI 971018 A FI971018 A FI 971018A FI 971018 A FI971018 A FI 971018A FI 971018 L FI971018 L FI 971018L
Authority
FI
Finland
Prior art keywords
pharmaceutical compounds
pharmaceutical
compounds
Prior art date
Application number
FI971018A
Other languages
English (en)
Swedish (sv)
Other versions
FI119754B (fi
FI971018A0 (fi
Inventor
Martin Jackman
Xue-Ping Popp
Friedrich Richter
Fritz Schmook
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27267447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI971018(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB9421612A external-priority patent/GB9421612D0/en
Priority claimed from GB9422306A external-priority patent/GB9422306D0/en
Priority claimed from GBGB9503553.1A external-priority patent/GB9503553D0/en
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of FI971018A0 publication Critical patent/FI971018A0/fi
Publication of FI971018L publication Critical patent/FI971018L/fi
Application granted granted Critical
Publication of FI119754B publication Critical patent/FI119754B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI971018A 1994-10-26 1997-03-11 Topikaalisia koostumuksia FI119754B (fi)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB9421612 1994-10-26
GB9421612A GB9421612D0 (en) 1994-10-26 1994-10-26 Organic compounds
GB9422306 1994-11-04
GB9422306A GB9422306D0 (en) 1994-11-04 1994-11-04 Organic compounds
GBGB9503553.1A GB9503553D0 (en) 1995-02-22 1995-02-22 Organic compounds
GB9503553 1995-02-22
PCT/EP1995/004208 WO1996013249A1 (en) 1994-10-26 1995-10-26 Pharmaceutical compositions
EP9504208 1995-10-26

Publications (3)

Publication Number Publication Date
FI971018A0 FI971018A0 (fi) 1997-03-11
FI971018L true FI971018L (fi) 1997-04-18
FI119754B FI119754B (fi) 2009-03-13

Family

ID=27267447

Family Applications (2)

Application Number Title Priority Date Filing Date
FI971018A FI119754B (fi) 1994-10-26 1997-03-11 Topikaalisia koostumuksia
FI20071025A FI119755B (fi) 1994-10-26 2007-12-28 Tyydyttämättömän rasva-alkoholin käyttö

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20071025A FI119755B (fi) 1994-10-26 2007-12-28 Tyydyttämättömän rasva-alkoholin käyttö

Country Status (25)

Country Link
US (1) US6352998B2 (fi)
EP (2) EP1147766B1 (fi)
JP (3) JP4155593B2 (fi)
KR (1) KR100434682B1 (fi)
CN (2) CN1089233C (fi)
AT (2) ATE299017T1 (fi)
AU (1) AU714254B2 (fi)
BR (1) BR9509530A (fi)
CA (1) CA2200966C (fi)
CY (1) CY2211B1 (fi)
CZ (1) CZ289773B6 (fi)
DE (3) DE69525957T2 (fi)
DK (2) DK0786986T3 (fi)
ES (2) ES2243369T3 (fi)
FI (2) FI119754B (fi)
GB (1) GB2308546B (fi)
HU (1) HU223840B1 (fi)
MX (1) MX9702699A (fi)
NO (2) NO316963B1 (fi)
NZ (2) NZ295170A (fi)
PL (1) PL184750B1 (fi)
PT (2) PT786986E (fi)
SI (1) SI0786986T1 (fi)
SK (1) SK284591B6 (fi)
WO (1) WO1996013249A1 (fi)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
CZ283516B6 (cs) * 1996-09-12 1998-04-15 Galena A.S. Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
TW450810B (en) * 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
DE19744621A1 (de) * 1997-10-09 1999-04-15 Muehlbauer Ernst Kg Mischung zur Verwendung als Wundverband
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
DE19802205A1 (de) * 1998-01-22 1999-07-29 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen, enthaltend erhöhte Elektrolytkonzentrationen
ID25908A (id) * 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
AR018330A1 (es) * 1998-04-27 2001-11-14 Fujisawa Pharmaceutical Co Composiciones farmaceuticas que comprenden macrolidos como agentes activos para la terapia y profilaxis de las enfermedades de la piel
GB9814640D0 (en) * 1998-07-06 1998-09-02 Fujisawa Pharmaceutical Co New use
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
GB0003932D0 (en) * 2000-02-18 2000-04-12 Novartis Ag Pharmaceutical compositions
KR20090130879A (ko) * 2001-02-16 2009-12-24 애보트 래보러토리즈 배스큘라 엔터프라이지즈 리미티드 Ｆｋ506을 포함하는 이식편
GB0108498D0 (en) * 2001-04-04 2001-05-23 Novartis Ag Organic Compounds
TWI324925B (en) * 2001-08-23 2010-05-21 Novartis Ag Ophthalmic composition
PE20030828A1 (es) * 2002-03-04 2003-11-04 Novartis Ag Composicion oftalmica que comprende ascomicina
GB0218996D0 (en) * 2002-08-14 2002-09-25 Novartis Ag Organic compounds
US20060115522A1 (en) * 2003-02-17 2006-06-01 Cipla Ltd Pharmaceutical composition
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307866D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307869D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
WO2005009436A1 (en) * 2003-07-31 2005-02-03 Pharmacia & Upjohn Company Llc Dispersible formulation of an anti-inflammatory agent
GB0408070D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Pharmaceutical formulations
PT1734927E (pt) * 2004-04-08 2012-09-05 Meda Pharma S A R L Composição em espuma de pimecrolimus contendo hexilenoglicol, opcionalmente álcool oleílico, dimetilisossorbida e/ou triglicéridos de cadeia média
GB0508827D0 (en) * 2005-04-29 2005-06-08 Novartis Ag Cosmeceutical composition
US9205080B2 (en) 2006-11-16 2015-12-08 Transderm, Inc. Methods of treating keratin hyperproliferation disorders using mTOR inhibitors
EP2016935A1 (en) * 2007-07-09 2009-01-21 Intendis GmbH Pharmaceutical composition for topical application of poorly soluble compounds
CN101288643B (zh) * 2008-06-17 2012-11-14 杨喜鸿 含有他克莫司的凝胶剂组合物及其制备方法和药物应用
EP2308468A1 (en) * 2009-10-08 2011-04-13 Novaliq GmbH Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
GB0917817D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
GB0917816D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
WO2012011192A1 (ja) * 2010-07-23 2012-01-26 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
JP5674786B2 (ja) * 2010-07-23 2015-02-25 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
CN102552253A (zh) * 2012-01-17 2012-07-11 唯美度科技（北京）有限公司 一种祛痘用皮肤外用剂
WO2013111817A1 (ja) * 2012-01-25 2013-08-01 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
EP2948134B1 (en) * 2013-01-24 2020-03-04 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mtor inhibitors
MX367121B (es) * 2013-08-02 2019-08-06 Laboratorio Raam De Sahuayo S A De C V Composición sólida estable de inmunosupresores.
DE102013222164A1 (de) * 2013-10-31 2015-04-30 Deb Ip Limited Stabilisierte multiple Emulsionen als Hautschutzprodukt
US10765665B2 (en) 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
CN105663027B (zh) * 2016-04-01 2018-12-18 中国人民解放军广州军区武汉总医院 西罗莫司外用制剂、其制备方法及用途
JP6932180B2 (ja) * 2016-04-04 2021-09-08 エムシー２・セラピューティクス・リミテッドＭＣ２ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ タクロリムスを含む局所組成物
US10722499B2 (en) 2017-01-06 2020-07-28 Palvella Therapeutics, Inc. Anyhydrous compositions of mTOR inhibitors and methods of use
KR101973065B1 (ko) 2017-09-13 2019-04-26 (주)썬테크 풍력 발전기 및 풍력 발전기의 블레이드 팁
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
KR101995905B1 (ko) 2018-03-27 2019-07-04 (주)썬테크 풍력 발전기 및 풍력 발전기의 발전모터
WO2019233722A1 (en) * 2018-06-08 2019-12-12 Almirall, S.A. Pharmaceutical composition comprising tacrolimus
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
WO2024213629A1 (en) * 2023-04-11 2024-10-17 Bausch Health Ireland Limited Topical compositions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4299826A (en) 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
DK175235B1 (da) 1987-11-09 2004-07-19 Novartis Ag Ny anvendelse af azatricycloderivater og farmaceutiske præparater med indhold deraf
JP2799208B2 (ja) 1987-12-09 1998-09-17 フアイソンズ・ピーエルシー マクロ環状化合物
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
DE10299040I2 (de) * 1989-11-09 2006-08-24 Novartis Ag Heteroatome enthaltende tricyclische Verbindungen
US5061700A (en) 1989-11-16 1991-10-29 Gordon Jay Dow Glyceryl acetate ointment vehicles
WO1991013899A1 (en) 1990-03-12 1991-09-19 Fujisawa Pharmaceutical Co., Ltd. Tricyclo compounds
JPH05507915A (ja) 1990-06-11 1993-11-11 藤沢薬品工業株式会社 特発性血小板減少性紫斑病およびバセドウ病治療薬製造のためのｆｋ５０６等のマクロライド化合物の用途
MY110418A (en) 1990-07-02 1998-05-30 Novartis Ag Heteroatoms-containing tricyclic compounds.
EP0474126B1 (en) * 1990-09-04 1997-03-19 Fujisawa Pharmaceutical Co., Ltd. Ointments containing tricyclic compound
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
PH31204A (en) * 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
CA2054983A1 (en) 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
US5247076A (en) 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5252732A (en) 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
US5208241A (en) 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
HUT66531A (en) 1992-05-07 1994-12-28 Sandoz Ag Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
JPH06183970A (ja) * 1992-12-16 1994-07-05 Fujisawa Pharmaceut Co Ltd 医薬用組成物
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
MY110603A (en) 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
DE59409377D1 (de) 1993-10-22 2000-06-29 Hexal Ag Pharmazeutische zusammensetzung mit cyclosporin a, einen vitamin e derivat und einen emulgator

Also Published As

Publication number Publication date
EP1147766B1 (en) 2005-07-06
MX9702699A (es) 1997-06-28
EP1147766A2 (en) 2001-10-24
PL319599A1 (en) 1997-08-18
BR9509530A (pt) 1997-10-14
JP2012131827A (ja) 2012-07-12
CN100335063C (zh) 2007-09-05
CN1162259A (zh) 1997-10-15
CN1401325A (zh) 2003-03-12
JP5599422B2 (ja) 2014-10-01
SK52097A3 (en) 1997-09-10
FI119754B (fi) 2009-03-13
CY2211B1 (en) 2002-11-08
NZ331824A (en) 2000-01-28
PT786986E (pt) 2002-07-31
JPH10508588A (ja) 1998-08-25
DK1147766T3 (da) 2005-08-29
NO971951L (no) 1997-04-25
ATE214593T1 (de) 2002-04-15
FI971018A0 (fi) 1997-03-11
WO1996013249A1 (en) 1996-05-09
DE69534306T2 (de) 2006-04-27
ATE299017T1 (de) 2005-07-15
DE19581804T1 (de) 1998-01-22
DE69525957D1 (de) 2002-04-25
CZ289773B6 (cs) 2002-04-17
GB2308546A (en) 1997-07-02
NZ295170A (en) 1999-02-25
JP4155593B2 (ja) 2008-09-24
NO2004005I1 (no) 2004-09-20
DK0786986T3 (da) 2002-04-29
PL184750B1 (pl) 2002-12-31
HU223840B1 (hu) 2005-02-28
GB2308546B (en) 1999-06-02
AU3845195A (en) 1996-05-23
GB9707484D0 (en) 1997-05-28
CN1089233C (zh) 2002-08-21
NO971951D0 (no) 1997-04-25
HUT77140A (hu) 1998-03-02
US6352998B2 (en) 2002-03-05
PT1147766E (pt) 2005-11-30
CA2200966C (en) 2006-12-19
FI20071025L (fi) 2007-12-28
NO316963B1 (no) 2004-07-12
EP1147766A3 (en) 2001-10-31
CA2200966A1 (en) 1996-05-09
KR970706796A (ko) 1997-12-01
NO2004005I2 (no) 2007-06-11
EP0786986A1 (en) 1997-08-06
AU714254B2 (en) 1999-12-23
CZ123297A3 (en) 1997-08-13
US20010031769A1 (en) 2001-10-18
FI119755B (fi) 2009-03-13
SK284591B6 (sk) 2005-07-01
SI0786986T1 (en) 2002-06-30
KR100434682B1 (ko) 2004-08-18
JP2007145860A (ja) 2007-06-14
DE69525957T2 (de) 2002-11-14
HK1053611A1 (en) 2003-10-31
DE69534306D1 (de) 2005-08-11
ES2243369T3 (es) 2005-12-01
ES2173978T3 (es) 2002-11-01
EP0786986B1 (en) 2002-03-20

Similar Documents

Publication Publication Date Title
FI970995L (fi) Farmaseuttisia yhdisteitä
FI971018L (fi) Farmaseuttisia yhdisteitä
FI971279A0 (fi) Lääkkeitä
DK0777671T3 (da) Spiro-azabicykliske forbindelser
FI971260A7 (fi) 1-asyyli-4-alifatyyliaminopiperidiiniyhdisteet
FI973243L (fi) Uusi farmaseuttinen yhdistelmä
DK0769017T3 (da) Terapeutiske forbindelser
FI954243A7 (fi) Farmaseuttiset yhdisteet
NO972937D0 (no) Farmasöytiske piperazinforbindelser
BR9610214A (pt) Compostos farmacéuticos
BR9508339A (pt) Medicamento
NO934145L (no) Farmasöytiske forbindelser
BR9507768A (pt) Composição farmacêutica
FI931251A7 (fi) Farmaseuttisia yhdisteitä
FI970151A0 (fi) Viruksenvastaisesti vaikuttavia difluoristatoniyhdisteitä
ITMI942166A0 (it) Composizioni farmaceutiche miorilassanti
FI951155L (fi) Farmaseuttinen valmiste
FI964918L (fi) Lääkeainesuoloja
BR9509740A (pt) Compostos 18-nor-vitamina d
NO965448L (no) Farmasöytiske forbindelser
FI950737A7 (fi) Lääkkeitä
FI971971A7 (fi) Pyridatsinokinoliiniyhdisteitä
FI962738A0 (fi) Farmaseuttiset koostumukset
FI954050L (fi) Lääkekoostumuksia
NO962816D0 (no) Farmasöytiske forbindelser

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 119754

Country of ref document: FI

MM Patent lapsed
SPCG Supplementary protection certificate granted

Spc suppl protection certif: 397

Extension date: 20170315

MA Patent expired